Compare Dell Technologies Inc (DELL) vs Eli Lilly And Co (LLY) Price & Performance

Dell Technologies (DELL) trades at $578.96, up 0.9% with strong bullish momentum driven by AI server demand. The stock shows robust technical positioning above key support levels with a P/E of 33.42 and net income margin of 7.53%. Recent earnings beats and raised AI revenue guidance to $74 billion highlight operational strength. Analyst consensus remains positive with 55.6% buy ratings and a $566.35 price target.

Dell presents compelling growth prospects from its AI server backlog expansion and margin improvements, though elevated valuation and competitive pressures warrant caution. The company's guidance increase and dividend growth signal confidence, but investors should monitor execution risks in the rapidly evolving AI infrastructure market.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.